Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 44 | 2024 | 17328 | 1.810 |
Why?
|
South Africa | 16 | 2024 | 1840 | 1.210 |
Why?
|
CD4 Lymphocyte Count | 12 | 2024 | 2569 | 1.010 |
Why?
|
Alendronate | 4 | 2005 | 175 | 0.700 |
Why?
|
Viral Load | 7 | 2024 | 3329 | 0.640 |
Why?
|
Beauty Culture | 1 | 2018 | 41 | 0.620 |
Why?
|
Anti-HIV Agents | 14 | 2024 | 4518 | 0.610 |
Why?
|
Speech Disorders | 1 | 2018 | 180 | 0.570 |
Why?
|
Contraception | 1 | 2018 | 348 | 0.490 |
Why?
|
Hair | 1 | 2018 | 497 | 0.480 |
Why?
|
Ambulatory Care Facilities | 4 | 2024 | 933 | 0.470 |
Why?
|
Constipation | 1 | 2018 | 562 | 0.440 |
Why?
|
Medication Adherence | 4 | 2024 | 2166 | 0.440 |
Why?
|
Estrogens, Conjugated (USP) | 2 | 2005 | 276 | 0.420 |
Why?
|
Tuberculosis, Pulmonary | 1 | 2019 | 831 | 0.400 |
Why?
|
Patient Transfer | 1 | 2019 | 793 | 0.390 |
Why?
|
Autistic Disorder | 4 | 2021 | 1219 | 0.360 |
Why?
|
Lamivudine | 6 | 2017 | 365 | 0.360 |
Why?
|
Anxiety | 4 | 2024 | 4558 | 0.340 |
Why?
|
Feasibility Studies | 5 | 2024 | 5236 | 0.340 |
Why?
|
Hormone Replacement Therapy | 2 | 2005 | 751 | 0.340 |
Why?
|
Osteoporosis, Postmenopausal | 4 | 2007 | 396 | 0.330 |
Why?
|
Health Knowledge, Attitudes, Practice | 3 | 2022 | 3996 | 0.320 |
Why?
|
Anti-Retroviral Agents | 6 | 2022 | 1781 | 0.320 |
Why?
|
Decision Support Techniques | 1 | 2017 | 1998 | 0.290 |
Why?
|
Estrogen Replacement Therapy | 2 | 2005 | 1208 | 0.290 |
Why?
|
Models, Theoretical | 2 | 2017 | 3576 | 0.270 |
Why?
|
Medroxyprogesterone | 1 | 2005 | 35 | 0.260 |
Why?
|
Tuberculosis | 1 | 2019 | 2012 | 0.260 |
Why?
|
Adult | 54 | 2024 | 220781 | 0.260 |
Why?
|
Hip | 2 | 2017 | 255 | 0.260 |
Why?
|
Female | 72 | 2024 | 391875 | 0.250 |
Why?
|
Cost-Benefit Analysis | 9 | 2018 | 5491 | 0.250 |
Why?
|
Refugees | 3 | 2020 | 595 | 0.250 |
Why?
|
Reverse Transcriptase Inhibitors | 4 | 2017 | 621 | 0.240 |
Why?
|
Bone Density | 6 | 2017 | 3549 | 0.230 |
Why?
|
Antiretroviral Therapy, Highly Active | 6 | 2024 | 1896 | 0.230 |
Why?
|
Humans | 93 | 2024 | 760437 | 0.230 |
Why?
|
Benzoxazines | 4 | 2017 | 316 | 0.220 |
Why?
|
Progesterone Congeners | 1 | 2003 | 44 | 0.220 |
Why?
|
Pancreatitis | 2 | 2013 | 1096 | 0.210 |
Why?
|
Penicillins | 2 | 2016 | 406 | 0.210 |
Why?
|
Male | 62 | 2024 | 360035 | 0.200 |
Why?
|
Medroxyprogesterone Acetate | 1 | 2003 | 155 | 0.200 |
Why?
|
Brain Concussion | 2 | 2024 | 1403 | 0.200 |
Why?
|
Trichomonas Infections | 1 | 2022 | 41 | 0.200 |
Why?
|
Drug Monitoring | 2 | 2018 | 961 | 0.190 |
Why?
|
HIV-1 | 8 | 2020 | 6859 | 0.190 |
Why?
|
Stavudine | 5 | 2008 | 85 | 0.190 |
Why?
|
Bone Remodeling | 1 | 2005 | 581 | 0.190 |
Why?
|
Alkynes | 4 | 2017 | 320 | 0.190 |
Why?
|
Radiographic Image Enhancement | 3 | 2015 | 876 | 0.180 |
Why?
|
Forecasting | 2 | 2020 | 2925 | 0.180 |
Why?
|
Placebos | 3 | 2019 | 1661 | 0.180 |
Why?
|
Cyclopropanes | 4 | 2017 | 432 | 0.180 |
Why?
|
Acquired Immunodeficiency Syndrome | 2 | 2006 | 2199 | 0.170 |
Why?
|
Positive-Pressure Respiration | 2 | 2023 | 638 | 0.170 |
Why?
|
Didanosine | 4 | 2007 | 151 | 0.170 |
Why?
|
Life Expectancy | 2 | 2016 | 1240 | 0.160 |
Why?
|
Models, Economic | 3 | 2018 | 716 | 0.160 |
Why?
|
Pregnancy, Unwanted | 1 | 2018 | 24 | 0.160 |
Why?
|
Bacteremia | 2 | 2016 | 979 | 0.160 |
Why?
|
Motor Activity | 2 | 2005 | 2710 | 0.160 |
Why?
|
Nelfinavir | 3 | 2007 | 68 | 0.160 |
Why?
|
Chlamydia Infections | 1 | 2022 | 365 | 0.160 |
Why?
|
Clinical Trials as Topic | 3 | 2018 | 7996 | 0.150 |
Why?
|
Pica | 1 | 2018 | 37 | 0.150 |
Why?
|
Family Characteristics | 1 | 2023 | 1000 | 0.150 |
Why?
|
Community Health Services | 2 | 2020 | 656 | 0.150 |
Why?
|
Gonorrhea | 1 | 2022 | 346 | 0.150 |
Why?
|
Child Health Services | 2 | 2020 | 645 | 0.150 |
Why?
|
Dental Care | 1 | 2020 | 285 | 0.140 |
Why?
|
Data Interpretation, Statistical | 1 | 2007 | 2691 | 0.140 |
Why?
|
Psychomotor Performance | 1 | 2005 | 1880 | 0.140 |
Why?
|
Diazoxide | 3 | 2007 | 52 | 0.140 |
Why?
|
Cohort Studies | 10 | 2024 | 41366 | 0.140 |
Why?
|
Muscle Hypotonia | 1 | 2018 | 161 | 0.140 |
Why?
|
Dideoxynucleosides | 1 | 2017 | 134 | 0.140 |
Why?
|
Drug Hypersensitivity | 2 | 2016 | 917 | 0.140 |
Why?
|
Algorithms | 4 | 2019 | 14002 | 0.140 |
Why?
|
Staphylococcal Infections | 2 | 2016 | 1409 | 0.140 |
Why?
|
Proportional Hazards Models | 3 | 2020 | 12429 | 0.140 |
Why?
|
Attention Deficit and Disruptive Behavior Disorders | 1 | 2018 | 306 | 0.140 |
Why?
|
Middle Aged | 35 | 2024 | 220382 | 0.130 |
Why?
|
Intraoperative Care | 1 | 2020 | 766 | 0.130 |
Why?
|
Sputum | 1 | 2019 | 506 | 0.130 |
Why?
|
Cardioplegic Solutions | 2 | 2007 | 122 | 0.130 |
Why?
|
Pain Measurement | 2 | 2024 | 3546 | 0.130 |
Why?
|
Respiratory Mechanics | 1 | 2020 | 699 | 0.130 |
Why?
|
Treatment Failure | 2 | 2017 | 2642 | 0.130 |
Why?
|
Sexually Transmitted Diseases | 1 | 2022 | 662 | 0.130 |
Why?
|
Eczema | 1 | 2018 | 245 | 0.130 |
Why?
|
Absorptiometry, Photon | 4 | 2017 | 1736 | 0.130 |
Why?
|
Cross-Sectional Studies | 7 | 2022 | 26063 | 0.130 |
Why?
|
HIV | 4 | 2018 | 1582 | 0.130 |
Why?
|
Probiotics | 1 | 2019 | 378 | 0.130 |
Why?
|
Vitamin D Deficiency | 1 | 2005 | 1384 | 0.130 |
Why?
|
Educational Status | 1 | 2023 | 2518 | 0.120 |
Why?
|
Smoking Cessation | 2 | 2017 | 2053 | 0.120 |
Why?
|
Mass Screening | 4 | 2021 | 5424 | 0.120 |
Why?
|
Public Sector | 1 | 2017 | 267 | 0.120 |
Why?
|
Indinavir | 2 | 2005 | 73 | 0.120 |
Why?
|
Employee Performance Appraisal | 1 | 2015 | 86 | 0.120 |
Why?
|
Financing, Personal | 1 | 2017 | 309 | 0.120 |
Why?
|
Random Allocation | 1 | 2019 | 2388 | 0.120 |
Why?
|
Drug Substitution | 1 | 2017 | 288 | 0.120 |
Why?
|
Influenza Vaccines | 1 | 2022 | 763 | 0.120 |
Why?
|
Young Adult | 12 | 2024 | 59068 | 0.120 |
Why?
|
Vitamin D | 2 | 2005 | 3303 | 0.120 |
Why?
|
Abdomen | 1 | 2020 | 1127 | 0.120 |
Why?
|
Income | 1 | 2023 | 1874 | 0.120 |
Why?
|
Needs Assessment | 1 | 2020 | 1139 | 0.110 |
Why?
|
Prevalence | 6 | 2022 | 15698 | 0.110 |
Why?
|
HIV Integrase Inhibitors | 1 | 2015 | 165 | 0.110 |
Why?
|
Social Support | 2 | 2020 | 2167 | 0.110 |
Why?
|
AIDS Serodiagnosis | 1 | 2014 | 220 | 0.110 |
Why?
|
Zidovudine | 4 | 2008 | 624 | 0.110 |
Why?
|
Myocardial Reperfusion Injury | 3 | 2007 | 480 | 0.110 |
Why?
|
Adolescent | 13 | 2024 | 88196 | 0.110 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2015 | 285 | 0.110 |
Why?
|
Lung Diseases | 1 | 2023 | 1909 | 0.100 |
Why?
|
Heart Arrest | 1 | 2023 | 1502 | 0.100 |
Why?
|
Pilot Projects | 7 | 2024 | 8611 | 0.100 |
Why?
|
Drug Combinations | 2 | 2017 | 2043 | 0.100 |
Why?
|
Models, Statistical | 4 | 2019 | 5078 | 0.100 |
Why?
|
Tomography, Spiral Computed | 1 | 2014 | 273 | 0.100 |
Why?
|
Double-Blind Method | 6 | 2007 | 12320 | 0.100 |
Why?
|
Indomethacin | 1 | 2013 | 326 | 0.100 |
Why?
|
Internationality | 1 | 2018 | 1001 | 0.100 |
Why?
|
Dietary Supplements | 1 | 2005 | 3405 | 0.100 |
Why?
|
Models, Educational | 1 | 2015 | 373 | 0.100 |
Why?
|
Health Services Needs and Demand | 1 | 2020 | 1403 | 0.100 |
Why?
|
Anesthesia | 1 | 2023 | 1588 | 0.100 |
Why?
|
Research Design | 1 | 2007 | 6168 | 0.100 |
Why?
|
United States | 14 | 2021 | 72202 | 0.090 |
Why?
|
Aging | 4 | 2020 | 8689 | 0.090 |
Why?
|
Prospective Studies | 14 | 2023 | 54339 | 0.090 |
Why?
|
Mind-Body Therapies | 2 | 2024 | 279 | 0.090 |
Why?
|
Influenza, Human | 1 | 2022 | 1517 | 0.090 |
Why?
|
Radiography, Dual-Energy Scanned Projection | 1 | 2013 | 200 | 0.090 |
Why?
|
Health Care Costs | 3 | 2018 | 3240 | 0.090 |
Why?
|
Computer Simulation | 3 | 2019 | 6230 | 0.090 |
Why?
|
Drugs, Generic | 1 | 2015 | 447 | 0.090 |
Why?
|
Self Report | 2 | 2024 | 3721 | 0.090 |
Why?
|
Aged | 26 | 2020 | 168840 | 0.090 |
Why?
|
Research Support as Topic | 1 | 2015 | 697 | 0.090 |
Why?
|
Smoking | 2 | 2017 | 9046 | 0.090 |
Why?
|
Cholangiopancreatography, Endoscopic Retrograde | 1 | 2013 | 505 | 0.090 |
Why?
|
Depression | 2 | 2021 | 8104 | 0.090 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 2 | 2014 | 1218 | 0.080 |
Why?
|
Continuity of Patient Care | 1 | 2017 | 1069 | 0.080 |
Why?
|
Homosexuality, Male | 1 | 2018 | 1333 | 0.080 |
Why?
|
Treatment Outcome | 12 | 2024 | 64591 | 0.080 |
Why?
|
Developmental Disabilities | 1 | 2018 | 1508 | 0.080 |
Why?
|
Primary Health Care | 3 | 2021 | 4674 | 0.080 |
Why?
|
Drug Therapy, Combination | 5 | 2007 | 6297 | 0.080 |
Why?
|
HIV Protease Inhibitors | 3 | 2008 | 432 | 0.080 |
Why?
|
Body Composition | 3 | 2007 | 2421 | 0.080 |
Why?
|
Oxazines | 2 | 2015 | 348 | 0.080 |
Why?
|
Contrast Media | 4 | 2015 | 5310 | 0.080 |
Why?
|
Family | 1 | 2020 | 3189 | 0.080 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2014 | 732 | 0.080 |
Why?
|
Infant | 3 | 2020 | 36183 | 0.080 |
Why?
|
RNA, Viral | 1 | 2017 | 2846 | 0.080 |
Why?
|
Point-of-Care Systems | 1 | 2017 | 1212 | 0.080 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 1 | 2015 | 699 | 0.080 |
Why?
|
Uganda | 3 | 2020 | 1332 | 0.080 |
Why?
|
Anti-Bacterial Agents | 3 | 2016 | 7424 | 0.080 |
Why?
|
Cooperative Behavior | 1 | 2015 | 1504 | 0.080 |
Why?
|
Academic Medical Centers | 2 | 2015 | 2757 | 0.080 |
Why?
|
Staphylococcus aureus | 1 | 2016 | 1459 | 0.080 |
Why?
|
Osteocalcin | 2 | 2007 | 274 | 0.070 |
Why?
|
Mortality | 1 | 2019 | 2897 | 0.070 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2020 | 4369 | 0.070 |
Why?
|
Geranyltranstransferase | 1 | 2007 | 5 | 0.070 |
Why?
|
Faculty, Medical | 1 | 2015 | 1202 | 0.070 |
Why?
|
Time Factors | 11 | 2020 | 39947 | 0.070 |
Why?
|
Research | 1 | 2015 | 1977 | 0.070 |
Why?
|
Radiation Injuries | 1 | 2014 | 1185 | 0.070 |
Why?
|
Trust | 2 | 2022 | 530 | 0.070 |
Why?
|
Child | 9 | 2021 | 80086 | 0.070 |
Why?
|
Vascular Diseases | 1 | 2015 | 1161 | 0.070 |
Why?
|
Program Evaluation | 1 | 2015 | 2493 | 0.070 |
Why?
|
Isotonic Solutions | 1 | 2006 | 116 | 0.070 |
Why?
|
Testosterone | 2 | 2007 | 2471 | 0.070 |
Why?
|
Health Services Accessibility | 2 | 2020 | 5421 | 0.060 |
Why?
|
Pregnancy | 4 | 2022 | 29831 | 0.060 |
Why?
|
Delivery of Health Care | 2 | 2020 | 5332 | 0.060 |
Why?
|
Socioeconomic Factors | 1 | 2019 | 7817 | 0.060 |
Why?
|
Alkaline Phosphatase | 2 | 2007 | 866 | 0.060 |
Why?
|
Body Fat Distribution | 1 | 2006 | 245 | 0.060 |
Why?
|
Nucleosides | 1 | 2005 | 131 | 0.060 |
Why?
|
Densitometry | 1 | 2005 | 151 | 0.060 |
Why?
|
Collagen Type I | 2 | 2007 | 616 | 0.060 |
Why?
|
Anti-Infective Agents, Local | 1 | 2007 | 247 | 0.060 |
Why?
|
Abdominal Fat | 1 | 2006 | 221 | 0.060 |
Why?
|
Pediatrics | 1 | 2020 | 3593 | 0.060 |
Why?
|
Canada | 2 | 2020 | 2119 | 0.060 |
Why?
|
Bone and Bones | 2 | 2005 | 2566 | 0.060 |
Why?
|
Hydroxyurea | 1 | 2005 | 282 | 0.060 |
Why?
|
Lactates | 1 | 2005 | 404 | 0.060 |
Why?
|
Hyperinsulinism | 1 | 2007 | 400 | 0.060 |
Why?
|
Kidney Neoplasms | 2 | 2014 | 4241 | 0.060 |
Why?
|
Thiazolidinediones | 1 | 2007 | 461 | 0.060 |
Why?
|
Minerals | 1 | 2005 | 284 | 0.060 |
Why?
|
Comorbidity | 1 | 2018 | 10494 | 0.060 |
Why?
|
Interleukin-2 | 3 | 2005 | 1891 | 0.060 |
Why?
|
HN Protein | 1 | 2003 | 8 | 0.050 |
Why?
|
Kidney | 3 | 2014 | 7046 | 0.050 |
Why?
|
Femur Neck | 1 | 2005 | 314 | 0.050 |
Why?
|
Blood Specimen Collection | 1 | 2005 | 238 | 0.050 |
Why?
|
Drug Administration Schedule | 4 | 2020 | 4849 | 0.050 |
Why?
|
Lung Neoplasms | 2 | 2018 | 13312 | 0.050 |
Why?
|
Macaca fascicularis | 1 | 2005 | 901 | 0.050 |
Why?
|
Cardiotonic Agents | 1 | 2006 | 539 | 0.050 |
Why?
|
Calcium | 2 | 2007 | 5726 | 0.050 |
Why?
|
Cholinergic Fibers | 1 | 2003 | 69 | 0.050 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 1 | 2018 | 3702 | 0.050 |
Why?
|
Melanoma | 3 | 2010 | 5704 | 0.050 |
Why?
|
Epilepsy | 1 | 2018 | 3286 | 0.050 |
Why?
|
Carotid Artery Thrombosis | 1 | 2002 | 50 | 0.050 |
Why?
|
Schools | 2 | 2023 | 1488 | 0.050 |
Why?
|
Telemedicine | 1 | 2020 | 3027 | 0.050 |
Why?
|
Pulmonary Eosinophilia | 1 | 2003 | 78 | 0.050 |
Why?
|
Paclitaxel | 1 | 2010 | 1732 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2024 | 10180 | 0.050 |
Why?
|
Respiratory Syncytial Viruses | 1 | 2003 | 168 | 0.050 |
Why?
|
Child, Preschool | 3 | 2020 | 42209 | 0.050 |
Why?
|
Post-Concussion Syndrome | 1 | 2024 | 243 | 0.050 |
Why?
|
Aged, 80 and over | 9 | 2018 | 58859 | 0.050 |
Why?
|
Tomography, X-Ray Computed | 3 | 2014 | 20551 | 0.050 |
Why?
|
Postoperative Complications | 2 | 2023 | 15627 | 0.050 |
Why?
|
Albuminuria | 1 | 2005 | 650 | 0.050 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2005 | 793 | 0.050 |
Why?
|
Multicenter Studies as Topic | 2 | 2023 | 1703 | 0.050 |
Why?
|
Mitochondria, Heart | 1 | 2002 | 229 | 0.050 |
Why?
|
Risk Factors | 11 | 2019 | 74055 | 0.050 |
Why?
|
Postural Balance | 1 | 2005 | 621 | 0.050 |
Why?
|
Stents | 1 | 2013 | 3177 | 0.050 |
Why?
|
Prosencephalon | 1 | 2003 | 305 | 0.050 |
Why?
|
Interleukin-13 | 1 | 2003 | 375 | 0.050 |
Why?
|
Colonic Diseases, Functional | 1 | 2000 | 39 | 0.050 |
Why?
|
Area Under Curve | 1 | 2005 | 1633 | 0.050 |
Why?
|
Body Weight | 3 | 2006 | 4614 | 0.040 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2010 | 11729 | 0.040 |
Why?
|
Oxygen Consumption | 1 | 2007 | 1859 | 0.040 |
Why?
|
Diphosphonates | 1 | 2005 | 636 | 0.040 |
Why?
|
Sulfonamides | 1 | 2010 | 1973 | 0.040 |
Why?
|
Dehydroepiandrosterone | 1 | 2021 | 258 | 0.040 |
Why?
|
Simian immunodeficiency virus | 1 | 2005 | 808 | 0.040 |
Why?
|
Specimen Handling | 1 | 2005 | 703 | 0.040 |
Why?
|
Stroke | 2 | 2018 | 9745 | 0.040 |
Why?
|
Biomarkers, Pharmacological | 1 | 2020 | 162 | 0.040 |
Why?
|
Dacarbazine | 1 | 2002 | 559 | 0.040 |
Why?
|
Pyrazoles | 1 | 2010 | 2007 | 0.040 |
Why?
|
Africa South of the Sahara | 1 | 2022 | 743 | 0.040 |
Why?
|
Carcinoma, Renal Cell | 2 | 2005 | 3159 | 0.040 |
Why?
|
Biomedical Research | 1 | 2015 | 3421 | 0.040 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2019 | 12127 | 0.040 |
Why?
|
Head and Neck Neoplasms | 1 | 2013 | 2891 | 0.040 |
Why?
|
Metformin | 1 | 2007 | 905 | 0.040 |
Why?
|
Infarction, Middle Cerebral Artery | 1 | 2002 | 485 | 0.040 |
Why?
|
Hypertension | 1 | 2019 | 8527 | 0.040 |
Why?
|
Macaca mulatta | 1 | 2005 | 2322 | 0.040 |
Why?
|
Femur | 1 | 2005 | 1308 | 0.040 |
Why?
|
Estrogens | 1 | 2005 | 1519 | 0.040 |
Why?
|
Walking | 1 | 2005 | 1199 | 0.040 |
Why?
|
Observer Variation | 2 | 2015 | 2604 | 0.040 |
Why?
|
Bone Density Conservation Agents | 1 | 2005 | 795 | 0.040 |
Why?
|
Case Management | 1 | 2020 | 272 | 0.040 |
Why?
|
Respiratory Syncytial Virus Infections | 1 | 2003 | 366 | 0.040 |
Why?
|
Pituitary-Adrenal System | 1 | 2021 | 549 | 0.040 |
Why?
|
Mozambique | 1 | 2017 | 55 | 0.040 |
Why?
|
Quality of Life | 1 | 2019 | 13338 | 0.040 |
Why?
|
Accidental Falls | 1 | 2005 | 1066 | 0.040 |
Why?
|
Statistics, Nonparametric | 2 | 2017 | 2852 | 0.040 |
Why?
|
Skin Neoplasms | 2 | 2010 | 5815 | 0.040 |
Why?
|
Universities | 1 | 2023 | 993 | 0.040 |
Why?
|
Reproducibility of Results | 4 | 2019 | 20078 | 0.040 |
Why?
|
Rural Population | 2 | 2018 | 2279 | 0.040 |
Why?
|
Adipose Tissue | 2 | 2006 | 3306 | 0.040 |
Why?
|
Fentanyl | 1 | 2000 | 435 | 0.040 |
Why?
|
Hypothalamo-Hypophyseal System | 1 | 2021 | 698 | 0.030 |
Why?
|
North America | 1 | 2020 | 1275 | 0.030 |
Why?
|
Tissue Plasminogen Activator | 1 | 2002 | 1163 | 0.030 |
Why?
|
Collagen | 1 | 2005 | 2637 | 0.030 |
Why?
|
Insurance, Health, Reimbursement | 1 | 2020 | 385 | 0.030 |
Why?
|
Methicillin | 1 | 2016 | 62 | 0.030 |
Why?
|
Pain Threshold | 1 | 2000 | 603 | 0.030 |
Why?
|
Activities of Daily Living | 1 | 2005 | 2420 | 0.030 |
Why?
|
Endothelium, Vascular | 1 | 2008 | 4430 | 0.030 |
Why?
|
Boston | 2 | 2007 | 9326 | 0.030 |
Why?
|
Regression Analysis | 3 | 2016 | 6340 | 0.030 |
Why?
|
Postmenopause | 1 | 2005 | 2513 | 0.030 |
Why?
|
Appointments and Schedules | 1 | 2020 | 443 | 0.030 |
Why?
|
Sex Characteristics | 1 | 2006 | 2633 | 0.030 |
Why?
|
Myocardial Ischemia | 1 | 2006 | 2110 | 0.030 |
Why?
|
Kenya | 1 | 2018 | 757 | 0.030 |
Why?
|
Demography | 2 | 2015 | 1648 | 0.030 |
Why?
|
HIV-Associated Lipodystrophy Syndrome | 2 | 2007 | 138 | 0.030 |
Why?
|
Brachiocephalic Veins | 1 | 2015 | 22 | 0.030 |
Why?
|
Subclavian Vein | 1 | 2015 | 58 | 0.030 |
Why?
|
Forearm | 1 | 2017 | 427 | 0.030 |
Why?
|
Voluntary Programs | 1 | 2014 | 48 | 0.030 |
Why?
|
Attitude | 1 | 2020 | 776 | 0.030 |
Why?
|
beta-Lactams | 1 | 2016 | 157 | 0.030 |
Why?
|
Iopamidol | 1 | 2015 | 186 | 0.030 |
Why?
|
Blood Circulation | 1 | 2015 | 249 | 0.030 |
Why?
|
Skin Tests | 1 | 2016 | 637 | 0.030 |
Why?
|
Michigan | 1 | 2015 | 339 | 0.030 |
Why?
|
Hypoglycemic Agents | 1 | 2007 | 3076 | 0.030 |
Why?
|
Registries | 2 | 2020 | 8216 | 0.030 |
Why?
|
Blood Glucose | 2 | 2005 | 6380 | 0.030 |
Why?
|
Phlebography | 1 | 2015 | 326 | 0.030 |
Why?
|
Jugular Veins | 1 | 2015 | 210 | 0.030 |
Why?
|
Health Resources | 1 | 2020 | 935 | 0.030 |
Why?
|
Obesity | 3 | 2021 | 12918 | 0.030 |
Why?
|
Mitochondria | 1 | 2007 | 3624 | 0.030 |
Why?
|
Tanzania | 1 | 2018 | 1385 | 0.030 |
Why?
|
Administration, Rectal | 1 | 2013 | 70 | 0.030 |
Why?
|
Budgets | 1 | 2015 | 229 | 0.030 |
Why?
|
Vancomycin | 1 | 2016 | 503 | 0.030 |
Why?
|
Hydrocortisone | 1 | 2021 | 1815 | 0.030 |
Why?
|
Clinical Competence | 2 | 2020 | 4777 | 0.030 |
Why?
|
Biostatistics | 1 | 2015 | 164 | 0.030 |
Why?
|
Clinical Laboratory Techniques | 1 | 2018 | 747 | 0.030 |
Why?
|
Sex Factors | 1 | 2007 | 10538 | 0.030 |
Why?
|
Writing | 1 | 2015 | 199 | 0.030 |
Why?
|
C-Reactive Protein | 1 | 2004 | 3822 | 0.030 |
Why?
|
Peptides | 1 | 2005 | 4338 | 0.030 |
Why?
|
Incidence | 2 | 2015 | 21322 | 0.030 |
Why?
|
Insulin Resistance | 2 | 2005 | 3956 | 0.030 |
Why?
|
Age Factors | 2 | 2007 | 18379 | 0.030 |
Why?
|
Retrospective Studies | 7 | 2016 | 80430 | 0.030 |
Why?
|
Authorship | 1 | 2015 | 283 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2020 | 2326 | 0.030 |
Why?
|
Survivors | 1 | 2023 | 2369 | 0.030 |
Why?
|
Faculty | 1 | 2015 | 383 | 0.030 |
Why?
|
Pandemics | 2 | 2022 | 8623 | 0.030 |
Why?
|
Kidney Function Tests | 1 | 2014 | 675 | 0.020 |
Why?
|
Radiation Tolerance | 1 | 2014 | 479 | 0.020 |
Why?
|
Delayed-Action Preparations | 1 | 2015 | 961 | 0.020 |
Why?
|
Brazil | 1 | 2016 | 1224 | 0.020 |
Why?
|
Anxiety Disorders | 1 | 2023 | 2717 | 0.020 |
Why?
|
Wounds and Injuries | 1 | 2024 | 2483 | 0.020 |
Why?
|
Subtraction Technique | 1 | 2014 | 511 | 0.020 |
Why?
|
Early Diagnosis | 1 | 2016 | 1183 | 0.020 |
Why?
|
Lipids | 3 | 2007 | 3342 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2018 | 1722 | 0.020 |
Why?
|
Feedback | 1 | 2015 | 791 | 0.020 |
Why?
|
Spine | 1 | 2017 | 1118 | 0.020 |
Why?
|
Pyridones | 1 | 2015 | 807 | 0.020 |
Why?
|
Rabbits | 2 | 2007 | 4780 | 0.020 |
Why?
|
Eosinophils | 1 | 2015 | 947 | 0.020 |
Why?
|
Vaccination | 1 | 2022 | 3375 | 0.020 |
Why?
|
Microbial Sensitivity Tests | 1 | 2016 | 1952 | 0.020 |
Why?
|
Immunotherapy | 1 | 2005 | 4649 | 0.020 |
Why?
|
Urban Population | 1 | 2017 | 2032 | 0.020 |
Why?
|
Risk | 2 | 2015 | 9605 | 0.020 |
Why?
|
Pulmonary Veins | 1 | 2015 | 746 | 0.020 |
Why?
|
Heart Atria | 1 | 2015 | 1347 | 0.020 |
Why?
|
Patient Acceptance of Health Care | 1 | 2022 | 3190 | 0.020 |
Why?
|
Tumor Burden | 1 | 2014 | 1887 | 0.020 |
Why?
|
Cognition | 1 | 2005 | 6973 | 0.020 |
Why?
|
Teaching | 1 | 2015 | 1169 | 0.020 |
Why?
|
Heart Ventricles | 2 | 2015 | 3815 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2005 | 10188 | 0.020 |
Why?
|
Recovery of Function | 1 | 2018 | 2975 | 0.020 |
Why?
|
Lung | 2 | 2023 | 9973 | 0.020 |
Why?
|
Drug Costs | 1 | 2015 | 1179 | 0.020 |
Why?
|
Allergens | 1 | 2015 | 1410 | 0.020 |
Why?
|
Health Personnel | 1 | 2021 | 3331 | 0.020 |
Why?
|
Triage | 1 | 2014 | 986 | 0.020 |
Why?
|
Neoplasm Metastasis | 2 | 2010 | 4903 | 0.020 |
Why?
|
Brachial Artery | 1 | 2008 | 366 | 0.020 |
Why?
|
Apoptosis | 1 | 2002 | 9468 | 0.020 |
Why?
|
Ritonavir | 1 | 2008 | 329 | 0.020 |
Why?
|
Communication | 1 | 2020 | 3868 | 0.020 |
Why?
|
Parents | 1 | 2020 | 3563 | 0.020 |
Why?
|
Artifacts | 1 | 2015 | 1898 | 0.020 |
Why?
|
Pulmonary Artery | 1 | 2015 | 1938 | 0.020 |
Why?
|
Pyrimidinones | 1 | 2008 | 384 | 0.020 |
Why?
|
Decision Support Systems, Clinical | 1 | 2015 | 1172 | 0.020 |
Why?
|
Myocardial Reperfusion | 1 | 2007 | 338 | 0.020 |
Why?
|
Waist-Hip Ratio | 1 | 2007 | 518 | 0.020 |
Why?
|
Neoplasms | 1 | 2014 | 22083 | 0.020 |
Why?
|
Piperazines | 1 | 2015 | 2519 | 0.020 |
Why?
|
Coronary Artery Disease | 1 | 2004 | 6388 | 0.020 |
Why?
|
Exercise | 1 | 2021 | 5874 | 0.020 |
Why?
|
Sodium Fluoride | 1 | 2005 | 65 | 0.020 |
Why?
|
Caregivers | 1 | 2017 | 2232 | 0.010 |
Why?
|
Oxalates | 1 | 2005 | 98 | 0.010 |
Why?
|
Blood Preservation | 1 | 2005 | 168 | 0.010 |
Why?
|
Analgesics, Opioid | 1 | 2000 | 3792 | 0.010 |
Why?
|
Ambulatory Care | 1 | 2015 | 2771 | 0.010 |
Why?
|
Adenocarcinoma, Clear Cell | 1 | 2005 | 217 | 0.010 |
Why?
|
Survival Analysis | 1 | 2016 | 10075 | 0.010 |
Why?
|
Diet | 1 | 2021 | 8058 | 0.010 |
Why?
|
Potassium Channels | 1 | 2006 | 537 | 0.010 |
Why?
|
Hospitals | 1 | 2017 | 3873 | 0.010 |
Why?
|
Magnesium | 1 | 2007 | 809 | 0.010 |
Why?
|
Blood Pressure | 1 | 2019 | 8479 | 0.010 |
Why?
|
Acidosis, Lactic | 1 | 2005 | 145 | 0.010 |
Why?
|
Body Size | 1 | 2006 | 463 | 0.010 |
Why?
|
Receptors, Interleukin-4 | 1 | 2003 | 64 | 0.010 |
Why?
|
Respiratory Syncytial Virus Vaccines | 1 | 2003 | 37 | 0.010 |
Why?
|
Potassium | 1 | 2007 | 1311 | 0.010 |
Why?
|
Adenine | 1 | 2008 | 986 | 0.010 |
Why?
|
Vaccines, Inactivated | 1 | 2003 | 179 | 0.010 |
Why?
|
Viremia | 1 | 2005 | 707 | 0.010 |
Why?
|
Cytokines | 2 | 2010 | 7377 | 0.010 |
Why?
|
Injections, Subcutaneous | 1 | 2003 | 678 | 0.010 |
Why?
|
In Situ Nick-End Labeling | 1 | 2002 | 609 | 0.010 |
Why?
|
bcl-2-Associated X Protein | 1 | 2002 | 282 | 0.010 |
Why?
|
Perfusion | 1 | 2006 | 1374 | 0.010 |
Why?
|
Formaldehyde | 1 | 2003 | 358 | 0.010 |
Why?
|
Cerebral Infarction | 1 | 2006 | 982 | 0.010 |
Why?
|
Vaccinia virus | 1 | 2003 | 331 | 0.010 |
Why?
|
Brain Neoplasms | 1 | 2002 | 9003 | 0.010 |
Why?
|
Vinblastine | 1 | 2002 | 488 | 0.010 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2006 | 1337 | 0.010 |
Why?
|
Neutralization Tests | 1 | 2003 | 728 | 0.010 |
Why?
|
Species Specificity | 1 | 2005 | 2417 | 0.010 |
Why?
|
Antibody Specificity | 1 | 2003 | 1060 | 0.010 |
Why?
|
Cytoplasm | 1 | 2005 | 1511 | 0.010 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2002 | 427 | 0.010 |
Why?
|
Maximum Tolerated Dose | 1 | 2003 | 882 | 0.010 |
Why?
|
Interleukin-12 | 1 | 2003 | 583 | 0.010 |
Why?
|
Adenosine Triphosphate | 1 | 2007 | 1989 | 0.010 |
Why?
|
Diabetes Mellitus | 1 | 2019 | 5835 | 0.010 |
Why?
|
Immunohistochemistry | 2 | 2005 | 11070 | 0.010 |
Why?
|
Caspase 3 | 1 | 2002 | 729 | 0.010 |
Why?
|
Insulin | 2 | 2006 | 6591 | 0.010 |
Why?
|
Injections, Intravenous | 1 | 2002 | 1379 | 0.010 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2002 | 629 | 0.010 |
Why?
|
Glucose Tolerance Test | 1 | 2003 | 1178 | 0.010 |
Why?
|
Creatinine | 1 | 2005 | 1898 | 0.010 |
Why?
|
Caspases | 1 | 2002 | 876 | 0.010 |
Why?
|
Disease Susceptibility | 1 | 2006 | 1790 | 0.010 |
Why?
|
Microscopy, Electron | 1 | 2002 | 2560 | 0.010 |
Why?
|
Receptors, Opioid, mu | 1 | 2000 | 167 | 0.010 |
Why?
|
Viral Envelope Proteins | 1 | 2003 | 640 | 0.010 |
Why?
|
Interleukin-4 | 1 | 2003 | 1130 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2020 | 39078 | 0.010 |
Why?
|
Models, Biological | 1 | 2015 | 9462 | 0.010 |
Why?
|
Immunization | 1 | 2003 | 1226 | 0.010 |
Why?
|
HIV Antibodies | 1 | 2005 | 1302 | 0.010 |
Why?
|
Interferon-alpha | 1 | 2002 | 920 | 0.010 |
Why?
|
Dyslipidemias | 1 | 2005 | 868 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2013 | 14661 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2013 | 12969 | 0.010 |
Why?
|
Family Health | 1 | 2003 | 1257 | 0.010 |
Why?
|
Infusions, Intravenous | 1 | 2002 | 2217 | 0.010 |
Why?
|
Th2 Cells | 1 | 2003 | 1054 | 0.010 |
Why?
|
Cardiopulmonary Bypass | 1 | 2002 | 1094 | 0.010 |
Why?
|
Disease Progression | 1 | 2014 | 13484 | 0.010 |
Why?
|
Cisplatin | 1 | 2002 | 1647 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2016 | 26280 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2002 | 1404 | 0.010 |
Why?
|
Animals | 5 | 2007 | 168253 | 0.010 |
Why?
|
Rectum | 1 | 2000 | 892 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 2003 | 6206 | 0.010 |
Why?
|
Ventricular Function, Left | 1 | 2006 | 3876 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2002 | 6525 | 0.010 |
Why?
|
Swine | 1 | 2002 | 5915 | 0.010 |
Why?
|
Genotype | 1 | 2007 | 12976 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2002 | 6813 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2000 | 6230 | 0.010 |
Why?
|
Antibodies, Viral | 1 | 2003 | 3155 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2007 | 14565 | 0.010 |
Why?
|
Proto-Oncogene Proteins | 1 | 2002 | 4509 | 0.010 |
Why?
|
Cell Line | 1 | 2003 | 15598 | 0.000 |
Why?
|
Cell Line, Tumor | 1 | 2005 | 16945 | 0.000 |
Why?
|
Survival Rate | 1 | 2002 | 12698 | 0.000 |
Why?
|
Mice, Knockout | 1 | 2003 | 14397 | 0.000 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2007 | 15867 | 0.000 |
Why?
|
Prognosis | 1 | 2005 | 29551 | 0.000 |
Why?
|
Severity of Illness Index | 1 | 2002 | 15820 | 0.000 |
Why?
|
Inflammation | 1 | 2003 | 10746 | 0.000 |
Why?
|
Case-Control Studies | 1 | 2000 | 22097 | 0.000 |
Why?
|
Alzheimer Disease | 1 | 2003 | 8579 | 0.000 |
Why?
|
Cardiovascular Diseases | 1 | 2005 | 15476 | 0.000 |
Why?
|
Mice | 1 | 2003 | 81402 | 0.000 |
Why?
|
Magnetic Resonance Imaging | 1 | 2002 | 36362 | 0.000 |
Why?
|